It doesn't look like the company will end up in the arms of an acquirer soon, after all.

Merck & Company Inc (NYSE:MRK) has ceased discussions to acquire biotechnology firm Revolution Medicines Inc (NASDAQ:RVMD), following a failure to reach an agreement on the company’s valuation.

Merck & Co. is no longer in talks to acquire biotech firm Revolution Medicines Inc. after the two companies couldn’t agree on ...

Revolution Medicines shares drop after Merck buyout talks collapse over price. Deal was valued at $28-32B before negotiations ...

Revolution Medicines shares tumbled in premarket trading Monday after The Wall Street Journal reported that drugmaker Merck is no longer in talks to buy the cancer-drug biotech. Shares of Revolution, ...

Revolution Medicines surged on AbbVie buyout rumors but pulled back after denial. Learn what's next for RVMD stock and why it is rated a Sell.

The pharmaceutical giant had been in talks to buy the cancer drug developer in a transaction that could have valued ...

Revolution Medicines, Inc. (NASDAQ:RVMD) is one of the stocks Jim Cramer talked about, along with market froth. Cramer ...

US pharmaceutical group Merck is in talks to buy Revolution Medicines, a cancer drugmaker with a market capitalisation of more than $20bn in what would be the latest big deal in the red-hot ...

That is according to the Wall Street Journal, which has said MSD failed to reach an agreement with Revolution on a fair price for the business, which has a cancer-focused pipeline headed by ...

Get the live share price of Revolution Medicines Inc (RVMD), including intraday charts, historical performance, key financials, and market updates. Track the latest US stock market activity.

Jan 25 (Reuters) - Merck is no longer in discussions to buy cancer drug developer Revolution Medicines, the Wall Street ...